Figure 3.
Deletion of RBM39 leads to an extensively altered splicing pattern in MM cells. (A) Number and percentage of differentially spliced events in MM.1S treated with RBM39 shRNA vs control scr (n = 2). (B) Events of exclusion or inclusion exon in differently spliced types in panel A. (C) Percent of differentially spliced events in panel A that overlap with RBM39 binding from anti-RBM39 RIP. (D) Number and percentage of differentially spliced events in MM.1S treated with indisulam vs dimethyl sulfoxide (n = 3). (E) Events of exclusion or inclusion exon in differently spliced types in panel D. (F) Percent of differentially spliced events in panel D that overlap with RBM39 binding from anti-RBM39 RIP. (G) GO analysis of AS events (ΔPSI > 0.4) in MM.1S treated with RBM39 shRNA vs control. (H) KEGG pathway analysis of differentially expressed genes in MM.1S treated with RBM39 shRNA vs control. (I) GO analysis of AS events (ΔPSI > 0.4) in H929 treated with RBM39 shRNA vs control (n = 3). (J) GO analysis of differentially expressed genes in H929 treated with RBM39 shRNA vs control. A3SSs, alternative 3’ splice sites; A5SSs, alternative 5’ splice sites; MXEs, mutually exclusive exons; RI, retained intron.

Deletion of RBM39 leads to an extensively altered splicing pattern in MM cells. (A) Number and percentage of differentially spliced events in MM.1S treated with RBM39 shRNA vs control scr (n = 2). (B) Events of exclusion or inclusion exon in differently spliced types in panel A. (C) Percent of differentially spliced events in panel A that overlap with RBM39 binding from anti-RBM39 RIP. (D) Number and percentage of differentially spliced events in MM.1S treated with indisulam vs dimethyl sulfoxide (n = 3). (E) Events of exclusion or inclusion exon in differently spliced types in panel D. (F) Percent of differentially spliced events in panel D that overlap with RBM39 binding from anti-RBM39 RIP. (G) GO analysis of AS events (ΔPSI > 0.4) in MM.1S treated with RBM39 shRNA vs control. (H) KEGG pathway analysis of differentially expressed genes in MM.1S treated with RBM39 shRNA vs control. (I) GO analysis of AS events (ΔPSI > 0.4) in H929 treated with RBM39 shRNA vs control (n = 3). (J) GO analysis of differentially expressed genes in H929 treated with RBM39 shRNA vs control. A3SSs, alternative 3’ splice sites; A5SSs, alternative 5’ splice sites; MXEs, mutually exclusive exons; RI, retained intron.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal